AUTHOR=Ding Qi-You , Tian Jia-Xing , Li Min , Lian Feng-Mei , Zhao Lin-Hua , Wei Xiu-Xiu , Han Lin , Zheng Yu-Jiao , Gao Ze-Zheng , Yang Hao-Yu , Fang Xin-Yi , Tong Xiao-lin 

TITLE=Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota

JOURNAL=Frontiers in Cellular and Infection Microbiology

VOLUME=Volume 10 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2020.530160

DOI=10.3389/fcimb.2020.530160

ISSN=2235-2988

ABSTRACT=With improved standards of living, the incidence of multiple metabolic disorders, including hyperglycemia and hyperlipidemia has increased year by year, especially (major risk factors for cardiovascular disease), continues to increase. Emerging epidemiological data and clinical trials have shown the additional protective effects of some metabolic therapy drugs against cardiovascular diseases. A series of studies have found that these drugs may work by modulating the composition of gut microbiota. In this review, we provide a brief overview of the contribution of gut microbiota to both metabolic disorders and cardiovascular diseases, as well as the response of gut microbiota to metabolic therapy drugs with cardiovascular benefits. In this manner, we link the recent advances in microbiome studies on metabolic treatment drugs with their cardiovascular protective effects, suggesting that intestinal microorganisms may play a potential role in reducing cardiovascular risk factors. We also discuss the potential of microorganism-targeted therapeutics as novel treatment strategies for preventing and/or treating cardiovascular diseases and highlight the need to establish causal links between therapeutics for metabolic diseases, gut microbiota modulation, and cardiovascular protection.